NewGen IVF Group, Inc. (NASDAQ: NIVFW) is a provider of assisted reproductive technology (ART) services focused on helping individuals and couples navigate fertility challenges. The company offers a full spectrum of fertility treatments, from initial patient consultations and diagnostic evaluations to advanced reproductive procedures, all designed to support patients through each stage of their family-building journey.
The company’s core offerings include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and cryopreservation of embryos, oocytes, and sperm. In addition to its clinical services, NewGen IVF provides specialized laboratory diagnostics such as hormonal profiling, semen analysis, and endometrial receptivity assessments. By combining evidence-based protocols with cutting-edge laboratory technologies, the company aims to optimize success rates and ensure patient safety.
Headquartered in India, NewGen IVF operates a network of fertility and reproductive health centers across multiple states. The company’s management team brings together professionals with deep expertise in reproductive medicine, healthcare administration, and biotechnology. In 2023, NewGen IVF Group completed its listing on the Nasdaq, underscoring its commitment to expanding access to high-quality fertility care and advancing the standard of assisted reproduction services.
AI Generated. May Contain Errors.